@tekkare/romulus 0.1.251 → 0.1.253

This diff represents the content of publicly available package versions that have been released to one of the supported registries. The information contained in this diff is provided for informational purposes only and reflects changes between package versions as they appear in their respective public registries.
Files changed (267) hide show
  1. package/dist/module.json +1 -1
  2. package/dist/runtime/utils/projects.d.ts +8 -0
  3. package/dist/runtime/utils/projects.js +8 -5
  4. package/layer/app/app.config.ts +6 -0
  5. package/layer/app/components/OipPubmedSummary.vue +223 -0
  6. package/layer/app/components/OipResourceDrawer.vue +331 -0
  7. package/layer/app/components/OipResourceDrawerLink.vue +40 -0
  8. package/layer/app/components/OipResourceField.vue +41 -0
  9. package/layer/app/components/OipResourceGenericCard.vue +54 -0
  10. package/layer/app/components/OipResourceSource.vue +50 -0
  11. package/layer/app/components/OipResourceTags.vue +65 -0
  12. package/layer/app/components/OipResourceView.vue +107 -0
  13. package/layer/app/components/oip-drugs/fiches/AssociationFiche.vue +775 -0
  14. package/layer/app/components/oip-drugs/fiches/BrandFiche.vue +1111 -0
  15. package/layer/app/components/oip-drugs/fiches/IndicationFiche.vue +182 -0
  16. package/layer/app/components/oip-drugs/fiches/JoFiche.vue +101 -0
  17. package/layer/app/components/oip-drugs/fiches/PndsFiche.vue +279 -0
  18. package/layer/app/components/oip-drugs/heart/JoCard.vue +314 -0
  19. package/layer/app/components/oip-drugs/heart/TextHighlight.vue +326 -0
  20. package/layer/app/components/oip-drugs/heart/ansm/BrandCard.vue +187 -0
  21. package/layer/app/components/oip-drugs/heart/ansm/CisDetail.vue +363 -0
  22. package/layer/app/components/oip-drugs/heart/ansm/CisTable.vue +167 -0
  23. package/layer/app/components/oip-drugs/heart/associations/NationalAssemblyCard.vue +373 -0
  24. package/layer/app/components/oip-drugs/heart/associations/NationalAssemblyFiche.vue +372 -0
  25. package/layer/app/components/oip-drugs/heart/associations/TranscriptionCard.vue +55 -0
  26. package/layer/app/components/oip-drugs/heart/elastic/SourceContainerElastic.vue +103 -0
  27. package/layer/app/components/oip-drugs/heart/france/BrandGroupCard.vue +450 -0
  28. package/layer/app/components/oip-drugs/heart/mitm/Card.vue +199 -0
  29. package/layer/app/components/oip-drugs/heart/mitm/Source.vue +23 -0
  30. package/layer/app/components/oip-drugs/heart/mitm/details/Overview.vue +381 -0
  31. package/layer/app/components/oip-drugs/heart/put/Card.vue +212 -0
  32. package/layer/app/components/oip-drugs/heart/results/AccesCard.vue +696 -0
  33. package/layer/app/components/oip-drugs/heart/results/AlertCard.vue +342 -0
  34. package/layer/app/components/oip-drugs/heart/results/AsmrCursor.vue +229 -0
  35. package/layer/app/components/oip-drugs/heart/results/EvalCard.vue +370 -0
  36. package/layer/app/components/oip-drugs/heart/results/IndicCard.vue +743 -0
  37. package/layer/app/components/oip-drugs/heart/results/MatchExplain.vue +243 -0
  38. package/layer/app/components/oip-drugs/heart/results/PrefRows.vue +105 -0
  39. package/layer/app/components/oip-drugs/heart/results/details/HasHistory.vue +487 -0
  40. package/layer/app/components/oip-drugs/heart/results/details/InternationalCountryCard.vue +461 -0
  41. package/layer/app/components/oip-drugs/heart/results/details/InternationalOverview.vue +200 -0
  42. package/layer/app/components/oip-drugs/heart/results/details/InternationalPriceDrawer.vue +647 -0
  43. package/layer/app/components/oip-drugs/heart/results/details/Monograph.vue +128 -0
  44. package/layer/app/components/oip-drugs/heart/results/details/OpinionDrawer.vue +535 -0
  45. package/layer/app/components/oip-drugs/heart/results/details/PresentationDrawer.vue +738 -0
  46. package/layer/app/components/oip-drugs/heart/results/details/Price.vue +227 -0
  47. package/layer/app/components/oip-drugs/heart/results/details/PriceOverview.vue +1261 -0
  48. package/layer/app/components/oip-drugs/heart/results/details/RecordDrawer.vue +494 -0
  49. package/layer/app/components/oip-drugs/heart/results/details/RecordList.vue +426 -0
  50. package/layer/app/components/oip-drugs/heart/results/les/Card.vue +340 -0
  51. package/layer/app/components/oip-drugs/heart/results/les/Drawer.vue +67 -0
  52. package/layer/app/components/oip-drugs/heart/results/les/IndicationDetail.vue +149 -0
  53. package/layer/app/components/oip-drugs/heart/results/les/Source.vue +20 -0
  54. package/layer/app/components/oip-drugs/heart/results/les/SourceTag.vue +39 -0
  55. package/layer/app/components/oip-drugs/heart/searchPage/DynamicSource.vue +29 -0
  56. package/layer/app/components/oip-drugs/medicam/market/Chart.vue +121 -0
  57. package/layer/app/components/oip-drugs/outpatient/ProductEvolution.vue +236 -0
  58. package/layer/app/components/oip-drugs/resources/Ansm.vue +75 -0
  59. package/layer/app/components/oip-drugs/resources/Association.vue +30 -0
  60. package/layer/app/components/oip-drugs/resources/Brand.vue +65 -0
  61. package/layer/app/components/oip-drugs/resources/Contribution.vue +216 -0
  62. package/layer/app/components/oip-drugs/resources/Hospital.vue +151 -0
  63. package/layer/app/components/oip-drugs/resources/Indication.vue +54 -0
  64. package/layer/app/components/oip-drugs/resources/Jo.vue +57 -0
  65. package/layer/app/components/oip-drugs/resources/Medicam.vue +140 -0
  66. package/layer/app/components/oip-drugs/resources/Mitm.vue +84 -0
  67. package/layer/app/components/oip-drugs/resources/NationalAssembly.vue +93 -0
  68. package/layer/app/components/oip-drugs/resources/Outpatient.vue +97 -0
  69. package/layer/app/components/oip-drugs/resources/Pnds.vue +24 -0
  70. package/layer/app/components/oip-drugs/resources/Price.vue +106 -0
  71. package/layer/app/components/oip-drugs/resources/Put.vue +143 -0
  72. package/layer/app/components/oip-science/appel-a-projet/Cards.vue +162 -0
  73. package/layer/app/components/oip-science/clinical-trials/Cards.vue +382 -0
  74. package/layer/app/components/oip-science/clinical-trials/CardsGlobal.vue +273 -0
  75. package/layer/app/components/oip-science/clinical-trials/LinkedList.vue +366 -0
  76. package/layer/app/components/oip-science/clinical-trials/PairBadge.vue +25 -0
  77. package/layer/app/components/oip-science/clinical-trials/PairBody.vue +182 -0
  78. package/layer/app/components/oip-science/clinical-trials/SitesDrawer.vue +95 -0
  79. package/layer/app/components/oip-science/common/Form.vue +73 -0
  80. package/layer/app/components/oip-science/common/MatchAvgTag.vue +283 -0
  81. package/layer/app/components/oip-science/common/NoData.vue +16 -0
  82. package/layer/app/components/oip-science/common/ScoreBadge.vue +35 -0
  83. package/layer/app/components/oip-science/common/Source.vue +31 -0
  84. package/layer/app/components/oip-science/common/TableTags.vue +279 -0
  85. package/layer/app/components/oip-science/common/Timeline.vue +104 -0
  86. package/layer/app/components/oip-science/common/ToolTips.vue +89 -0
  87. package/layer/app/components/oip-science/cross/publicationPubmed.vue +484 -0
  88. package/layer/app/components/oip-science/crossData/CrossDataLocations.vue +71 -0
  89. package/layer/app/components/oip-science/ctgov/Investigators.vue +148 -0
  90. package/layer/app/components/oip-science/ctgov/Locations.vue +102 -0
  91. package/layer/app/components/oip-science/ctgov/Publications.vue +52 -0
  92. package/layer/app/components/oip-science/ctgov/Sponsors.vue +66 -0
  93. package/layer/app/components/oip-science/ctgov/StudyDescription.vue +1136 -0
  94. package/layer/app/components/oip-science/ctgov-centers/ClinicalTrials.vue +40 -0
  95. package/layer/app/components/oip-science/ctgov-centers/Publications.vue +50 -0
  96. package/layer/app/components/oip-science/ctgov-investigators/ClinicalTrials.vue +43 -0
  97. package/layer/app/components/oip-science/ctgov-investigators/Informations.vue +171 -0
  98. package/layer/app/components/oip-science/ctgov-investigators/Publications.vue +44 -0
  99. package/layer/app/components/oip-science/elastic/DateRangeFilter.vue +209 -0
  100. package/layer/app/components/oip-science/elastic/Filter.vue +719 -0
  101. package/layer/app/components/oip-science/elastic/MatchExplain.vue +152 -0
  102. package/layer/app/components/oip-science/establishments/Cards.vue +183 -0
  103. package/layer/app/components/oip-science/establishments/ClinicalTrials.vue +62 -0
  104. package/layer/app/components/oip-science/establishments/Hcps.vue +227 -0
  105. package/layer/app/components/oip-science/establishments/Informations.vue +263 -0
  106. package/layer/app/components/oip-science/establishments/LinkedList.vue +153 -0
  107. package/layer/app/components/oip-science/establishments/MatchedLabels.vue +194 -0
  108. package/layer/app/components/oip-science/establishments/PublicFinance.vue +62 -0
  109. package/layer/app/components/oip-science/euct/Investigators.vue +125 -0
  110. package/layer/app/components/oip-science/euct/Locations.vue +102 -0
  111. package/layer/app/components/oip-science/euct/Products.vue +101 -0
  112. package/layer/app/components/oip-science/euct/Publications.vue +89 -0
  113. package/layer/app/components/oip-science/euct/Sponsors.vue +86 -0
  114. package/layer/app/components/oip-science/euct/StudyDescription.vue +1075 -0
  115. package/layer/app/components/oip-science/euct-centers/ClinicalTrials.vue +40 -0
  116. package/layer/app/components/oip-science/euct-centers/Publications.vue +55 -0
  117. package/layer/app/components/oip-science/euct-investigators/ClinicalTrials.vue +41 -0
  118. package/layer/app/components/oip-science/euct-investigators/Informations.vue +171 -0
  119. package/layer/app/components/oip-science/euct-investigators/Publications.vue +51 -0
  120. package/layer/app/components/oip-science/hcps/AppelsAProjet.vue +62 -0
  121. package/layer/app/components/oip-science/hcps/Cards.vue +237 -0
  122. package/layer/app/components/oip-science/hcps/ClinicalTrials.vue +78 -0
  123. package/layer/app/components/oip-science/hcps/Informations.vue +296 -0
  124. package/layer/app/components/oip-science/hcps/LinkedList.vue +153 -0
  125. package/layer/app/components/oip-science/hcps/MatchedLabels.vue +207 -0
  126. package/layer/app/components/oip-science/hcps/Pubmed.vue +128 -0
  127. package/layer/app/components/oip-science/local/SliderTabs.vue +99 -0
  128. package/layer/app/components/oip-science/local/SliderTabsFull.vue +135 -0
  129. package/layer/app/components/oip-science/pubmed/Authors.vue +128 -0
  130. package/layer/app/components/oip-science/pubmed/Cards.vue +417 -0
  131. package/layer/app/components/oip-science/pubmed/ClinicalTrials.vue +71 -0
  132. package/layer/app/components/oip-science/resources/Phrc.vue +39 -0
  133. package/layer/app/composables/useOipChapterScroll.ts +43 -0
  134. package/layer/app/composables/useOipResourceHooks.ts +27 -0
  135. package/layer/app/composables/useOipResourceNav.ts +66 -0
  136. package/layer/app/composables/useOipResourceViews.ts +117 -0
  137. package/layer/app/composables/useOipResources.ts +83 -0
  138. package/layer/app/oip-drugs/PORTING.md +120 -0
  139. package/layer/app/oip-drugs/composables/useAssociationDetail.ts +220 -0
  140. package/layer/app/oip-drugs/composables/useAssociationExport.ts +63 -0
  141. package/layer/app/oip-drugs/composables/useAssociationLookup.ts +105 -0
  142. package/layer/app/oip-drugs/composables/useCardPrefOptions.ts +201 -0
  143. package/layer/app/oip-drugs/composables/useCurrency.ts +121 -0
  144. package/layer/app/oip-drugs/composables/useDirectusSources.ts +224 -0
  145. package/layer/app/oip-drugs/composables/useHeartBrandMatches.ts +112 -0
  146. package/layer/app/oip-drugs/composables/useHeartDetailSearches.ts +479 -0
  147. package/layer/app/oip-drugs/composables/useHeartIntlApprovals.ts +661 -0
  148. package/layer/app/oip-drugs/composables/useHeartLesIndication.ts +168 -0
  149. package/layer/app/oip-drugs/composables/useHeartMatchExplain.ts +231 -0
  150. package/layer/app/oip-drugs/composables/useHeartReports.ts +239 -0
  151. package/layer/app/oip-drugs/composables/useHeartSearchFields.ts +233 -0
  152. package/layer/app/oip-drugs/composables/useMergeByKey.ts +23 -0
  153. package/layer/app/oip-drugs/composables/useOipDrugsElastic.ts +621 -0
  154. package/layer/app/oip-drugs/composables/usePageEmpty.ts +58 -0
  155. package/layer/app/oip-drugs/composables/v-useSalesSource.ts +64 -0
  156. package/layer/app/oip-drugs/drugs.css +500 -0
  157. package/layer/app/oip-drugs/esIndices.ts +322 -0
  158. package/layer/app/oip-drugs/kinds.ts +264 -0
  159. package/layer/app/oip-drugs/locales/en.json +1571 -0
  160. package/layer/app/oip-drugs/locales/fr.json +1571 -0
  161. package/layer/app/oip-drugs/monographs/blincyto-has.vue +289 -0
  162. package/layer/app/oip-drugs/monographs/darzalex-has.vue +276 -0
  163. package/layer/app/oip-drugs/monographs/dupixent-has.vue +216 -0
  164. package/layer/app/oip-drugs/monographs/enhertu-has.vue +280 -0
  165. package/layer/app/oip-drugs/monographs/has-sein-2023.vue +1649 -0
  166. package/layer/app/oip-drugs/monographs/ibrance-has.vue +277 -0
  167. package/layer/app/oip-drugs/monographs/imfinzi-has.vue +293 -0
  168. package/layer/app/oip-drugs/monographs/keytruda-has.vue +334 -0
  169. package/layer/app/oip-drugs/monographs/kisqali-has.vue +201 -0
  170. package/layer/app/oip-drugs/monographs/opdivo-has.vue +231 -0
  171. package/layer/app/oip-drugs/monographs/ozempic-has.vue +186 -0
  172. package/layer/app/oip-drugs/monographs/tecentriq-has.vue +312 -0
  173. package/layer/app/oip-drugs/monographs/yescarta-has.vue +272 -0
  174. package/layer/app/oip-drugs/types/elastic.ts +113 -0
  175. package/layer/app/oip-drugs/types/es/agencies.ts +152 -0
  176. package/layer/app/oip-drugs/types/es/directory.ts +54 -0
  177. package/layer/app/oip-drugs/types/es/docByIndex.ts +151 -0
  178. package/layer/app/oip-drugs/types/es/openmedic.ts +67 -0
  179. package/layer/app/oip-drugs/types/es/outpatient.ts +71 -0
  180. package/layer/app/oip-drugs/types/es/portal.ts +130 -0
  181. package/layer/app/oip-drugs/types/es/retail.ts +107 -0
  182. package/layer/app/oip-drugs/types/es/statistics.ts +29 -0
  183. package/layer/app/oip-drugs/types/heart/CurrencyRate.ts +16 -0
  184. package/layer/app/oip-drugs/types/heart/ansm.ts +106 -0
  185. package/layer/app/oip-drugs/types/heart/tag.ts +29 -0
  186. package/layer/app/oip-drugs/utils/associationFields.ts +118 -0
  187. package/layer/app/oip-drugs/utils/contributions.ts +36 -0
  188. package/layer/app/oip-drugs/utils/countryMapping.ts +387 -0
  189. package/layer/app/oip-drugs/utils/esHighlight.ts +21 -0
  190. package/layer/app/oip-drugs/utils/exportSheets.ts +57 -0
  191. package/layer/app/oip-drugs/utils/heartIntlPrice.ts +228 -0
  192. package/layer/app/oip-drugs/utils/heartStyleAndFormat.ts +262 -0
  193. package/layer/app/oip-drugs/utils/heartStyleAnsm.ts +71 -0
  194. package/layer/app/oip-drugs/utils/latestDate.ts +31 -0
  195. package/layer/app/oip-drugs/utils/p-heartCardTags.ts +53 -0
  196. package/layer/app/oip-drugs/utils/priceExport.ts +269 -0
  197. package/layer/app/oip-drugs/utils/q-hasRatings.ts +43 -0
  198. package/layer/app/oip-drugs/utils/s-openCard.ts +20 -0
  199. package/layer/app/oip-drugs/utils/sourceUuids.ts +155 -0
  200. package/layer/app/oip-drugs/utils/styleAndFormat.ts +40 -0
  201. package/layer/app/oip-drugs/utils/v-salesSeries.ts +156 -0
  202. package/layer/app/oip-drugs/utils/v-scopeTags.ts +23 -0
  203. package/layer/app/oip-science/PORTING.md +93 -0
  204. package/layer/app/oip-science/assets/smartSelection.json +428 -0
  205. package/layer/app/oip-science/composables/useAuthorMatching.ts +342 -0
  206. package/layer/app/oip-science/composables/useCTCenter.ts +107 -0
  207. package/layer/app/oip-science/composables/useCTInvestigators.ts +107 -0
  208. package/layer/app/oip-science/composables/useEstablishmentCrossData.ts +139 -0
  209. package/layer/app/oip-science/composables/useEstablishmentMatching.ts +176 -0
  210. package/layer/app/oip-science/composables/useEuct.ts +418 -0
  211. package/layer/app/oip-science/composables/useEuctCenter.ts +107 -0
  212. package/layer/app/oip-science/composables/useEuctInvestigators.ts +107 -0
  213. package/layer/app/oip-science/composables/useGlobalClinicalTrials.ts +624 -0
  214. package/layer/app/oip-science/composables/useLinkedTrials.ts +83 -0
  215. package/layer/app/oip-science/composables/useOipElastic.ts +658 -0
  216. package/layer/app/oip-science/composables/useOipSearchExplain.ts +166 -0
  217. package/layer/app/oip-science/composables/usePubmed.ts +487 -0
  218. package/layer/app/oip-science/composables/useSearchFields.ts +153 -0
  219. package/layer/app/oip-science/indexConfig.json +794 -0
  220. package/layer/app/oip-science/locales/en.json +483 -0
  221. package/layer/app/oip-science/locales/fr.json +483 -0
  222. package/layer/app/oip-science/science.css +1182 -0
  223. package/layer/app/oip-science/utils/a-openCard.ts +23 -0
  224. package/layer/app/oip-science/utils/b-openCard.ts +35 -0
  225. package/layer/app/oip-science/utils/c-filterContext.ts +81 -0
  226. package/layer/app/oip-science/utils/f-types.ts +241 -0
  227. package/layer/app/oip-science/utils/frDiseaseTerms.ts +269 -0
  228. package/layer/app/oip-science/utils/matchMethod.ts +53 -0
  229. package/layer/app/oip-science/utils/sliderTabs.ts +13 -0
  230. package/layer/app/oip-science/utils/sources.ts +15 -0
  231. package/layer/app/oip-science/utils/styleAndFormat.ts +608 -0
  232. package/layer/app/oip-science/utils/toPresets.ts +7 -0
  233. package/layer/app/oip-science/utils/valueTable.ts +126 -0
  234. package/layer/app/plugins/oip-science-i18n.ts +17 -0
  235. package/layer/app/utils/oipFicheRoutes.ts +118 -0
  236. package/layer/app/utils/oipResources.ts +440 -0
  237. package/layer/nuxt.config.ts +22 -2
  238. package/layer/public/reports/blincyto-has.html +292 -0
  239. package/layer/public/reports/blincyto-has.pdf +0 -0
  240. package/layer/public/reports/darzalex-has.html +279 -0
  241. package/layer/public/reports/darzalex-has.pdf +0 -0
  242. package/layer/public/reports/dupixent-has.html +217 -0
  243. package/layer/public/reports/dupixent-has.pdf +0 -0
  244. package/layer/public/reports/enhertu-has.html +283 -0
  245. package/layer/public/reports/enhertu-has.pdf +0 -0
  246. package/layer/public/reports/has-sein-2023.html +1639 -0
  247. package/layer/public/reports/ibrance-has.html +280 -0
  248. package/layer/public/reports/ibrance-has.pdf +0 -0
  249. package/layer/public/reports/imfinzi-has.html +297 -0
  250. package/layer/public/reports/imfinzi-has.pdf +0 -0
  251. package/layer/public/reports/keytruda-has.html +337 -0
  252. package/layer/public/reports/keytruda-has.pdf +0 -0
  253. package/layer/public/reports/kisqali-has.html +202 -0
  254. package/layer/public/reports/kisqali-has.pdf +0 -0
  255. package/layer/public/reports/opdivo-has.html +232 -0
  256. package/layer/public/reports/opdivo-has.pdf +0 -0
  257. package/layer/public/reports/ozempic-has.html +188 -0
  258. package/layer/public/reports/ozempic-has.pdf +0 -0
  259. package/layer/public/reports/tecentriq-has.html +315 -0
  260. package/layer/public/reports/tecentriq-has.pdf +0 -0
  261. package/layer/public/reports/yescarta-has.html +275 -0
  262. package/layer/public/reports/yescarta-has.pdf +0 -0
  263. package/layer/server/api/oip/es.post.ts +99 -0
  264. package/layer/server/api/oip/pdf.get.ts +70 -0
  265. package/layer/server/api/oip/reports.get.ts +98 -0
  266. package/layer/server/api/oip/resource-types.get.ts +22 -0
  267. package/package.json +1 -1
package/layer/public/reports/imfinzi-has.html ADDED
@@ -0,0 +1,297 @@
1
+ <!DOCTYPE html>
2
+ <html lang="fr">
3
+ <head>
4
+ <meta charset="UTF-8">
5
+ <meta name="viewport" content="width=device-width, initial-scale=1.0">
6
+ <title>Imfinzi (durvalumab) : historique reglementaire HAS | Note Tekkare Intelligence</title>
7
+ <link rel="preconnect" href="https://fonts.googleapis.com">
8
+ <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
9
+ <link href="https://fonts.googleapis.com/css2?family=Caudex:ital,wght@0,400;0,700;1,400;1,700&family=Figtree:ital,wght@0,300..900;1,300..900&display=swap" rel="stylesheet">
10
+ <script src="https://unpkg.com/@phosphor-icons/web"></script>
11
+ <style>
12
+ :root{
13
+ --primary:#2100AD; --secondary:#B485FF; --darkest:#1E293B; --dark:#525670;
14
+ --medium:#878CA6; --light:#DBDEF0; --lightest:#F5F5F9; --bg:#F9F9FA; --white:#FFFFFF;
15
+ --success:#16A34A; --warning:#D97706; --error:#E53535;
16
+ --db:#EE5599;
17
+ }
18
+ *{box-sizing:border-box;margin:0;padding:0;}
19
+ sup{font-size:0.6em;vertical-align:super;line-height:0;}
20
+ body{font-family:'Figtree',Avenir,Arial,sans-serif;color:var(--darkest);background:var(--bg);line-height:1.55;-webkit-font-smoothing:antialiased;}
21
+ .wrap{max-width:920px;margin:0 auto;padding:0 24px 64px;}
22
+ em{font-family:'Caudex',Georgia,serif;font-style:normal;font-weight:700;color:var(--primary);}
23
+
24
+ .hero{background:url("https://rcd-media.com/skills/Background_Degrade_Blanc.png") center/cover no-repeat;padding:48px 24px 40px;border-bottom:1px solid var(--light);}
25
+ .hero-inner{max-width:920px;margin:0 auto;}
26
+ .hero img{height:32px;margin-bottom:28px;}
27
+ .eyebrow{font-size:11px;font-weight:700;letter-spacing:.14em;text-transform:uppercase;color:var(--primary);margin-bottom:10px;}
28
+ .hero-top{display:flex;justify-content:space-between;align-items:center;gap:16px;margin-bottom:26px;flex-wrap:wrap;}
29
+ .hero-date{font-family:'Figtree';font-size:12px;font-weight:600;color:var(--dark);white-space:nowrap;}
30
+ .eyebrow-row{display:flex;align-items:center;gap:12px;margin-bottom:12px;flex-wrap:wrap;}
31
+ .ti-badge{display:inline-flex;align-items:center;gap:7px;font-family:'Figtree';font-weight:700;font-size:11px;letter-spacing:.1em;text-transform:uppercase;padding:5px 13px;border-radius:4px;color:#fff;background:linear-gradient(90deg,#4DCCF7,#A06BF5,#FF5CF0);}
32
+ .eyebrow-row .eyebrow{margin-bottom:0;}
33
+ .produced{margin-top:20px;font-size:12px;font-weight:500;color:var(--dark);display:flex;align-items:center;gap:8px;flex-wrap:wrap;}
34
+ h1{font-family:'Figtree';font-weight:700;font-size:34px;color:var(--darkest);line-height:1.15;margin-bottom:8px;}
35
+ h1 .mol{font-family:'Caudex';font-weight:700;color:var(--primary);}
36
+ .sub{font-size:15px;color:var(--dark);max-width:640px;}
37
+
38
+ .kpis{display:grid;grid-template-columns:repeat(4,1fr);gap:14px;margin:-28px auto 0;max-width:920px;padding:0 24px;position:relative;z-index:2;}
39
+ .kpi{background:var(--white);border:1px solid var(--light);border-radius:8px;padding:16px 18px;box-shadow:0 2px 8px rgba(30,41,59,0.06);}
40
+ .kpi .n{font-family:'Caudex';font-weight:700;font-size:34px;color:var(--primary);line-height:1;}
41
+ .kpi .l{font-size:11px;color:var(--dark);margin-top:6px;line-height:1.3;}
42
+ .kpi.alert .n{color:var(--error);}
43
+
44
+ section{margin-top:44px;}
45
+ h2{font-family:'Figtree';font-weight:600;font-size:23px;color:var(--darkest);margin-bottom:6px;display:flex;align-items:center;gap:10px;}
46
+ h2 i{color:var(--primary);font-size:22px;}
47
+ .lead{font-size:14px;color:var(--dark);margin-bottom:20px;max-width:720px;}
48
+
49
+ .tl{position:relative;padding-left:26px;}
50
+ .tl::before{content:"";position:absolute;left:7px;top:6px;bottom:6px;width:2px;background:linear-gradient(180deg,#4DCCF7,#A06BF5,#FF5CF0);border-radius:2px;}
51
+ .yr{font-family:'Caudex';font-weight:700;font-size:15px;color:var(--primary);margin:22px 0 10px -26px;padding-left:26px;position:relative;}
52
+ .ev{position:relative;background:var(--white);border:1px solid var(--light);border-radius:8px;padding:12px 15px;margin-bottom:10px;box-shadow:0 2px 8px rgba(30,41,59,0.05);}
53
+ .ev::before{content:"";position:absolute;left:-22px;top:16px;width:9px;height:9px;border-radius:999px;background:var(--primary);border:2px solid var(--white);box-shadow:0 0 0 2px var(--light);}
54
+ .ev.refus::before{background:var(--error);box-shadow:0 0 0 2px #F9D3D3;}
55
+ .ev.restr::before{background:var(--warning);box-shadow:0 0 0 2px #F6E2C0;}
56
+ .ev-top{display:flex;flex-wrap:wrap;align-items:center;gap:8px;margin-bottom:4px;}
57
+ .date{font-size:11px;font-weight:700;color:var(--medium);letter-spacing:.03em;min-width:78px;}
58
+ .ind{font-size:14px;font-weight:600;color:var(--darkest);flex:1;min-width:180px;}
59
+ .code{font-size:10px;color:var(--medium);font-family:'Figtree';white-space:nowrap;}
60
+ .code a{color:inherit;text-decoration:none;border-bottom:1px dotted currentColor;}
61
+ .code a:hover{color:var(--primary);border-bottom-color:var(--primary);}
62
+ .badges{display:flex;gap:6px;flex-wrap:wrap;}
63
+ .b{font-size:10px;font-weight:700;padding:3px 8px;border-radius:4px;letter-spacing:.02em;white-space:nowrap;}
64
+ .b-smr{background:var(--lightest);color:var(--dark);border:1px solid var(--light);}
65
+ .b-a3{background:#E7F6EE;color:#0B7A38;}
66
+ .b-a4{background:#FEF4E6;color:#9A5B04;}
67
+ .b-a5{background:#FCE9E9;color:#A11B1B;}
68
+ .b-refus{background:var(--error);color:var(--white);}
69
+ .b-warn{background:#FEF4E6;color:#9A5B04;}
70
+ .b-na{background:var(--lightest);color:var(--medium);border:1px solid var(--light);}
71
+ .ctx{font-size:11px;color:var(--medium);margin-top:2px;}
72
+
73
+ .refbox{background:#FCE9E9;border:1px solid #F3B4B4;border-left:4px solid var(--error);border-radius:8px;padding:18px 20px;margin-bottom:14px;}
74
+ .refbox h3{font-family:'Figtree';font-weight:700;font-size:15px;color:#A11B1B;margin-bottom:4px;display:flex;align-items:center;gap:8px;}
75
+ .refbox .meta{font-size:11px;color:var(--dark);margin-bottom:8px;}
76
+ .refbox p{font-size:13px;color:var(--darkest);}
77
+ .restrict{background:#FEF7EC;border:1px solid #F3D9B0;border-left:4px solid var(--warning);border-radius:8px;padding:18px 20px;margin-bottom:14px;}
78
+ .restrict h3{font-family:'Figtree';font-weight:700;font-size:15px;color:#9A5B04;margin-bottom:4px;display:flex;align-items:center;gap:8px;}
79
+ .restrict .meta{font-size:11px;color:var(--dark);margin-bottom:8px;}
80
+ .restrict p{font-size:13px;color:var(--darkest);}
81
+
82
+ .dist{background:var(--white);border:1px solid var(--light);border-radius:8px;padding:20px;box-shadow:0 2px 8px rgba(30,41,59,0.05);}
83
+ .row{display:flex;align-items:center;gap:12px;margin-bottom:12px;}
84
+ .row:last-child{margin-bottom:0;}
85
+ .row .lab{font-size:12px;font-weight:600;color:var(--dark);width:150px;}
86
+ .bar{flex:1;height:22px;background:var(--lightest);border-radius:4px;overflow:hidden;}
87
+ .fill{height:100%;border-radius:4px;display:flex;align-items:center;justify-content:flex-end;padding-right:8px;color:var(--white);font-size:11px;font-weight:700;}
88
+
89
+ .takeaway{background:var(--white);border:1px solid var(--light);border-left:4px solid transparent;border-image:linear-gradient(180deg,#4DCCF7,#A06BF5,#FF5CF0) 1;border-radius:8px;padding:20px 22px;margin-top:36px;box-shadow:0 2px 8px rgba(30,41,59,0.06);}
90
+ .takeaway .tk-lab{font-size:11px;font-weight:700;letter-spacing:.12em;text-transform:uppercase;color:var(--primary);margin-bottom:8px;display:flex;align-items:center;gap:8px;}
91
+ .takeaway p{font-size:14.5px;color:var(--darkest);line-height:1.6;}
92
+ .takeaway em{font-family:'Caudex';font-weight:700;color:var(--primary);font-style:normal;}
93
+
94
+ .price-wrap{background:var(--white);border:1px solid var(--light);border-radius:8px;padding:22px;box-shadow:0 2px 8px rgba(30,41,59,0.05);}
95
+ .price-row{display:flex;align-items:center;gap:14px;margin-bottom:10px;}
96
+ .price-row:last-child{margin-bottom:0;}
97
+ .price-row .py{font-size:12px;font-weight:700;color:var(--dark);width:52px;}
98
+ .price-bar{flex:1;height:26px;background:var(--lightest);border-radius:4px;overflow:hidden;}
99
+ .price-fill{height:100%;border-radius:4px;background:linear-gradient(90deg,#2100AD,#B485FF);display:flex;align-items:center;justify-content:flex-end;padding-right:10px;color:#fff;font-size:11px;font-weight:700;}
100
+ .price-note{font-size:12px;color:var(--dark);margin-top:14px;}
101
+ .pill-sus{display:inline-block;font-size:10px;font-weight:700;padding:3px 9px;border-radius:4px;background:#EEF1FE;color:#183BA8;}
102
+ .pill-retro{display:inline-block;font-size:10px;font-weight:700;padding:3px 9px;border-radius:4px;background:#FCF0F5;color:#991144;}
103
+ .sku-table{width:100%;border-collapse:collapse;margin-bottom:18px;font-size:12.5px;background:var(--white);border:1px solid var(--light);border-radius:8px;overflow:hidden;box-shadow:0 2px 8px rgba(30,41,59,0.05);}
104
+ .sku-table thead th{background:var(--lightest);color:var(--dark);font-weight:700;font-size:11px;letter-spacing:.02em;text-align:left;padding:10px 12px;border-bottom:1px solid var(--light);}
105
+ .sku-table td{padding:10px 12px;border-bottom:1px solid var(--light);color:var(--darkest);vertical-align:top;}
106
+ .sku-table tr:last-child td{border-bottom:none;}
107
+ .sku-table td.num{font-family:'Caudex';font-weight:700;color:var(--primary);white-space:nowrap;}
108
+ .sku-table td .rg{font-size:10px;font-weight:700;color:var(--dark);}
109
+ .sku-cap{font-size:11px;color:var(--medium);margin:-8px 0 20px;}
110
+
111
+ .disclaimer-inner{display:flex;gap:10px;align-items:flex-start;background:var(--lightest);border:1px solid var(--light);border-radius:6px;padding:11px 14px;font-size:11.5px;color:var(--dark);line-height:1.5;}
112
+ .disclaimer-inner i{color:var(--primary);font-size:15px;margin-top:1px;flex-shrink:0;}
113
+
114
+ .b-pre{background:#EDE7FF;color:#3B1E8F;}
115
+ .b-post{background:#EEF1FE;color:#183BA8;}
116
+ .b-closed{background:#E7F6EE;color:#0B7A38;}
117
+ .b-ongoing{background:#FEF4E6;color:#9A5B04;}
118
+ .ap-stats{display:flex;gap:22px;flex-wrap:wrap;margin:4px 0 22px;}
119
+ .ap-stat{display:flex;flex-direction:column;gap:2px;}
120
+ .ap-stat .v{font-family:'Caudex';font-weight:700;font-size:26px;color:var(--primary);line-height:1;}
121
+ .ap-stat .k{font-size:11px;color:var(--dark);}
122
+
123
+ footer{margin-top:48px;padding-top:22px;border-top:1px solid var(--light);font-size:11px;color:var(--dark);}
124
+ footer .src{display:flex;align-items:flex-start;gap:8px;margin-bottom:14px;}
125
+ footer i{color:var(--primary);font-size:15px;margin-top:1px;}
126
+ .legal{display:flex;gap:11px;align-items:flex-start;margin-top:20px;padding:14px 16px;background:var(--lightest);border:1px solid var(--light);border-left:4px solid var(--primary);border-radius:6px;font-size:12px;color:var(--dark);line-height:1.55;}
127
+ .legal i{color:var(--primary);font-size:18px;margin-top:1px;flex-shrink:0;}
128
+ .legal strong{color:var(--darkest);}
129
+ .sig{font-size:10px;font-weight:700;letter-spacing:.12em;color:var(--medium);text-transform:uppercase;line-height:1.6;margin-top:18px;}
130
+ .db-tag{display:inline-block;font-size:10px;font-weight:700;padding:3px 8px;border-radius:4px;background:#FFF0F7;color:#991144;}
131
+
132
+ @media print{
133
+ body{-webkit-print-color-adjust:exact;print-color-adjust:exact;background:var(--white);}
134
+ a[href]:after{content:"";}
135
+ }
136
+ @media(max-width:640px){
137
+ .kpis{grid-template-columns:repeat(2,1fr);}
138
+ h1{font-size:26px;}
139
+ .row .lab{width:120px;}
140
+ }
141
+ </style>
142
+ </head>
143
+ <body>
144
+ <a href="/reports/imfinzi-has.pdf" download class="tk-dl-pdf" style="position:fixed;top:20px;right:20px;z-index:9999;display:inline-flex;align-items:center;gap:8px;padding:10px 16px;background:#2100AD;color:#fff;font-family:'Figtree',Avenir,Arial,sans-serif;font-size:13px;font-weight:700;text-decoration:none;border-radius:8px;box-shadow:0 4px 14px rgba(33,0,173,0.32);"><i class="ph-fill ph-file-pdf" style="font-size:16px;"></i>Télécharger le PDF</a>
145
+
146
+
147
+ <div class="hero">
148
+ <div class="hero-inner">
149
+ <div class="hero-top">
150
+ <img src="https://rcd-media.com/skills/Tekkare_Baseline_Bleu.svg" alt="Tekkare, Inspired by Healthcare" height="32">
151
+ <span class="hero-date">16 juillet 2026</span>
152
+ </div>
153
+ <div class="eyebrow-row">
154
+ <span class="ti-badge"><i class="ph-fill ph-sparkle" style="font-size:14px;"></i>Tekkare Intelligence</span>
155
+ <span class="eyebrow">Monographie réglementaire</span>
156
+ </div>
157
+ <h1><span class="mol">Imfinzi</span> (durvalumab)</h1>
158
+ <p class="sub">Sept ans d'avis de la HAS en France : de la première indication remboursée à la dernière, avec les niveaux de SMR / ASMR, les refus et l'accès précoce, cartographiés à partir des données structurées OIP.</p>
159
+ <div class="produced"><i class="ph-fill ph-database" style="color:var(--db);font-size:15px;"></i>Produced with <span class="db-tag">OIP Databank<sup>&reg;</sup></span></div>
160
+ </div>
161
+ </div>
162
+
163
+ <div class="kpis">
164
+ <div class="kpi"><div class="n">10</div><div class="l">avis de la Commission de la Transparence avec SMR / ASMR</div></div>
165
+ <div class="kpi"><div class="n">2019</div><div class="l">Première indication : CBNPC de stade III non opérable, consolidation post-chimioradiothérapie (6 févr. 2019)</div></div>
166
+ <div class="kpi"><div class="n">1</div><div class="l">avis noté ASMR III (modéré), le niveau maximal atteint (étude PACIFIC)</div></div>
167
+ <div class="kpi alert"><div class="n">1</div><div class="l">refus thérapeutique : SMR insuffisant (cancer du poumon)</div></div>
168
+ </div>
169
+
170
+ <div class="wrap">
171
+
172
+ <div class="legal" style="margin-top:28px;"><i class="ph-fill ph-warning-circle"></i><div><strong>Avertissement.</strong> Ce rapport est une aide à l'analyse. Il doit être validé par l'utilisateur avant tout usage officiel. Tekkare ne saurait être tenue responsable de son utilisation.</div></div>
173
+
174
+ <div class="takeaway">
175
+ <div class="tk-lab"><i class="ph-fill ph-lightbulb"></i>À retenir</div>
176
+ <p>Anti-PD-L1 d'AstraZeneca, Imfinzi a construit son accès sur une <em>indication phare</em>, le cancer bronchique non à petites cellules de stade III non opérable en consolidation après chimioradiothérapie (étude PACIFIC), seul avis à décrocher une ASMR III sur toute la trajectoire. Il s'est ensuite étendu à un <em>large maillage de localisations</em> (poumon à petites cellules, foie, voies biliaires, endomètre, vessie), presque toujours en association (trémélimumab, olaparib, chimiothérapie) et à valeur ajoutée systématiquement mineure (ASMR IV). Deux revers marquent les limites : un <em>refus récent dans le poumon</em> et un service médical rendu abaissé à Modéré pour une association de première ligne. Le prix recule d'environ un quart, et l'accès précoce est mobilisé de façon massive, onze décisions, comme rampe quasi systématique vers le remboursement.</p>
177
+ </div>
178
+
179
+ <section>
180
+ <h2><i class="ph-fill ph-chart-line-up"></i>Synthèse</h2>
181
+ <p class="lead">Depuis son inscription initiale dans le cancer bronchique non à petites cellules (CBNPC) de stade III non opérable en février 2019, le durvalumab s'est étendu à de nombreuses localisations tumorales solides : poumon (CBNPC et cancer bronchique à petites cellules), foie (carcinome hépatocellulaire), voies biliaires, endomètre et vessie. Le service médical rendu a été jugé <em>Important</em> dans huit des dix avis, avec un unique service insuffisant qui constitue le seul refus de prise en charge, et un abaissement à Modéré pour l'association durvalumab + trémélimumab en première ligne du CBNPC métastatique. L'amélioration du service médical rendu a atteint l'ASMR III (modéré) une seule fois, dans l'indication fondatrice issue de l'étude PACIFIC, et s'est ensuite maintenue au niveau mineur (ASMR IV), traduisant une valeur d'appoint plutôt que de rupture. La trajectoire se distingue par un recours intensif à l'accès précoce, en Pré comme en Post-AMM, qui a précédé la plupart des inscriptions de droit commun.</p>
182
+ </section>
183
+
184
+ <section>
185
+ <h2><i class="ph-fill ph-warning-octagon"></i>Refus et restrictions de prise en charge</h2>
186
+ <p class="lead">Un avis constitue un refus thérapeutique (SMR insuffisant). Un second a été assorti d'un service médical rendu abaissé à Modéré pour une association de première ligne.</p>
187
+
188
+ <div class="refbox">
189
+ <h3><i class="ph-fill ph-x-circle"></i>Refus thérapeutique, cancer du poumon</h3>
190
+ <div class="meta">CT-21398 · 22 oct. 2025 · SMR Insuffisant · ASMR Sans objet</div>
191
+ <p>La Commission a conclu à un service médical rendu insuffisant dans l'indication de l'AMM, fermant l'accès au remboursement dans ce cadre.</p>
192
+ </div>
193
+
194
+ <div class="restrict">
195
+ <h3><i class="ph-fill ph-arrow-bend-down-right"></i>Restriction : SMR abaissé à Modéré</h3>
196
+ <div class="meta">CT-20228 · 30 août 2023 · CBNPC métastatique 1re ligne, association durvalumab + trémélimumab + chimiothérapie (POSEIDON) · SMR Modéré · ASMR IV</div>
197
+ <p>Seul avis où le service médical rendu a été jugé <strong>Modéré</strong> et non Important. Le gain de survie globale est réel mais modeste (environ 2,3 mois), face à un comparateur (chimiothérapie seule) jugé non optimal, avec un surcroît de toxicité marqué (événements indésirables graves, immuno-médiés). L'apport par rapport aux alternatives disponibles n'a pas pu être quantifié.</p>
198
+ </div>
199
+ </section>
200
+
201
+ <section>
202
+ <h2><i class="ph-fill ph-chart-bar"></i>Répartition des SMR et ASMR</h2>
203
+ <div class="dist" style="margin-bottom:14px;">
204
+ <div class="row"><span class="lab">SMR Important</span><div class="bar"><div class="fill" style="width:100%;background:var(--success);">8</div></div></div>
205
+ <div class="row"><span class="lab">SMR Modéré</span><div class="bar"><div class="fill" style="width:13%;background:var(--warning);">1</div></div></div>
206
+ <div class="row"><span class="lab">SMR Insuffisant</span><div class="bar"><div class="fill" style="width:13%;background:var(--error);">1</div></div></div>
207
+ </div>
208
+ <div class="dist">
209
+ <div class="row"><span class="lab">ASMR IV (mineur)</span><div class="bar"><div class="fill" style="width:100%;background:var(--warning);">8</div></div></div>
210
+ <div class="row"><span class="lab">ASMR III (modéré)</span><div class="bar"><div class="fill" style="width:13%;background:var(--success);">1</div></div></div>
211
+ <div class="row"><span class="lab">Sans objet</span><div class="bar"><div class="fill" style="width:13%;background:var(--medium);">1</div></div></div>
212
+ </div>
213
+ </section>
214
+
215
+ <section>
216
+ <h2><i class="ph-fill ph-currency-eur"></i>Prix et remboursement</h2>
217
+ <p class="lead">Imfinzi est financé à l'hôpital <span class="pill-sus">inscrit sur la liste en sus</span>, après une phase de <span class="pill-retro">rétrocession</span> (2021 à 2023). Le tableau ci-dessous récapitule le prix à jour des deux présentations commercialisées.</p>
218
+
219
+ <table class="sku-table">
220
+ <thead>
221
+ <tr><th>Présentation</th><th>Régime</th><th>PFHT</th><th>Prix public</th><th>&euro; / mg</th><th>Dernière mise à jour</th></tr>
222
+ </thead>
223
+ <tbody>
224
+ <tr><td>Perfusion IV, flacon 500 mg (10 mL)<br><span class="rg">solution à diluer</span></td><td>Liste en sus</td><td class="num">1 670,51 &euro;</td><td class="num">1 705,59 &euro;</td><td class="num">3,41</td><td>11 févr. 2026</td></tr>
225
+ <tr><td>Perfusion IV, flacon 120 mg (2,4 mL)<br><span class="rg">solution à diluer</span></td><td>Liste en sus</td><td class="num">400,92 &euro;</td><td class="num">409,34 &euro;</td><td class="num">3,41</td><td>11 févr. 2026</td></tr>
226
+ </tbody>
227
+ </table>
228
+ <p class="sku-cap">Prix public hospitalier des présentations commercialisées, à la date de la dernière publication au Journal Officiel enregistrée dans les données OIP. Les deux flacons sont au même prix par mg (durvalumab dosé à 50 mg/mL).</p>
229
+
230
+ <p class="lead">Les barres ci-dessous retracent l'évolution de la <strong>PFHT (prix fabricant HT)</strong> du flacon de 500 mg, à SKU constante.</p>
231
+ <div class="price-wrap">
232
+ <div class="price-row"><span class="py">2020</span><div class="price-bar"><div class="price-fill" style="width:100.0%;">2 200,00 &euro;</div></div></div>
233
+ <div class="price-row"><span class="py">2022</span><div class="price-bar"><div class="price-fill" style="width:89.5%;">1 968,88 &euro;</div></div></div>
234
+ <div class="price-row"><span class="py">2023</span><div class="price-bar"><div class="price-fill" style="width:78.2%;">1 721,25 &euro;</div></div></div>
235
+ <div class="price-row"><span class="py">2026</span><div class="price-bar"><div class="price-fill" style="width:75.9%;">1 670,51 &euro;</div></div></div>
236
+ <div class="price-note"><strong>PFHT (prix fabricant HT)</strong> du <strong>flacon de 500 mg (10 mL)</strong>, à SKU constante. Recul d'environ <strong>24 %</strong> entre avril 2020 et février 2026, soit de <strong>4,40 &euro; à 3,34 &euro; par mg</strong>. Le flacon de 120 mg suit exactement la même trajectoire au mg. La baisse accompagne l'élargissement continu du périmètre remboursé et la sortie de l'accès précoce.</div>
237
+ </div>
238
+ <p class="lead" style="margin-top:16px;">Lecture pour l'accès au marché : une érosion de prix régulière, caractéristique d'une immunothérapie à large spectre dont le volume d'indications s'accroît, l'arbitrage volume contre prix étant assumé au fil des extensions.</p>
239
+ </section>
240
+
241
+ <section>
242
+ <h2><i class="ph-fill ph-rocket-launch"></i>Accès précoce : la rampe d'accès</h2>
243
+ <p class="lead">Avant le remboursement de droit commun, l'accès précoce a permis une mise à disposition en amont. Imfinzi en fait un usage intensif : 3 protocoles d'utilisation thérapeutique autorisés, au sein de 11 décisions d'accès précoce couvrant de nombreuses localisations.</p>
244
+ <div class="ap-stats">
245
+ <div class="ap-stat"><span class="v">3</span><span class="k">protocoles d'accès précoce</span></div>
246
+ <div class="ap-stat"><span class="v">1</span><span class="k">Pré-AMM (avant autorisation)</span></div>
247
+ <div class="ap-stat"><span class="v">2</span><span class="k">clôturés, convertis en remboursement</span></div>
248
+ <div class="ap-stat"><span class="v">11</span><span class="k">décisions d'accès précoce au catalogue</span></div>
249
+ </div>
250
+ <div class="tl">
251
+ <div class="yr">Protocoles autorisés, par date</div>
252
+ <div class="ev"><div class="ev-top"><span class="date">22 sept. 2022</span><span class="ind">Cancer des voies biliaires non résécable ou métastatique, 1re ligne (association gemcitabine + cisplatine) <span class="code"><a href="https://www.has-sante.fr/jcms/p_3372376/fr/imfinzi-durvalumab-cancer-des-voies-biliaires" target="_blank" rel="noopener">· AP-3372376</a></span></span><div class="badges"><span class="b b-post">Post-AMM</span><span class="b b-closed">Clôturé</span></div></div><div class="ctx">Remboursement de droit commun <strong style="color:var(--primary);">environ 9 mois</strong> après (avis CT-20175)</div></div>
253
+ <div class="ev"><div class="ev-top"><span class="date">23 févr. 2023</span><span class="ind">Carcinome hépatocellulaire avancé ou non résécable, 1re ligne (association trémélimumab) <span class="code"><a href="https://www.has-sante.fr/jcms/p_3418037/fr/imfinzi-durvalumab-carcinome-hepato-cellulaire" target="_blank" rel="noopener">· AP-3418037</a></span></span><div class="badges"><span class="b b-post">Post-AMM</span><span class="b b-closed">Clôturé</span></div></div><div class="ctx">Remboursement de droit commun <strong style="color:var(--primary);">environ 3 mois</strong> après (avis CT-20226)</div></div>
254
+ <div class="ev"><div class="ev-top"><span class="date">20 nov. 2024</span><span class="ind">Cancer bronchique à petites cellules de stade limité, consolidation post-chimioradiothérapie (étude ADRIATIC) <span class="code"><a href="https://www.has-sante.fr/jcms/p_3562956/fr/imfinzi-durvalumab-cancer-bronchique-a-petites-cellules-cbpc" target="_blank" rel="noopener">· AP-3562956</a></span></span><div class="badges"><span class="b b-pre">Pré-AMM</span><span class="b b-ongoing">En cours</span></div></div><div class="ctx">Remboursement de droit commun <strong style="color:var(--primary);">environ 13 mois</strong> après (avis CT-21376)</div></div>
255
+ </div>
256
+ <p class="lead" style="margin-top:16px;">Lecture stratégique : sur les trois protocoles structurés, deux sont clôturés (bascule vers le remboursement une fois l'avis de Transparence rendu) et un reste en cours en Pré-AMM. Le délai médian entre accès précoce et avis de Transparence est d'environ <strong>9 mois</strong> (de 3 à 13 mois). Au-delà de ces trois protocoles, le catalogue recense onze décisions d'accès précoce, signe d'un recours systématique dans chaque nouvelle localisation (poumon, endomètre, vessie, estomac).</p>
257
+ <div style="margin-top:14px;"><div class="disclaimer-inner"><i class="ph-fill ph-info"></i><div>Délais estimés par rapprochement de localisation, non d'indication exacte. L'écart entre les 11 décisions au catalogue et les 3 protocoles structurés correspond à des renouvellements et à des extensions non recoupés une à une ici.</div></div></div>
258
+ </section>
259
+
260
+ <section>
261
+ <h2><i class="ph-fill ph-clock-countdown"></i>Frise complète des avis de la Transparence</h2>
262
+ <p class="lead">Chaque avis de la Commission de la Transparence portant une note SMR / ASMR, par ordre chronologique. Les décisions d'accès précoce, qui ne portent pas de SMR / ASMR, sont présentées dans la section dédiée.</p>
263
+
264
+ <div class="tl">
265
+
266
+ <div class="yr">2019</div>
267
+ <div class="ev"><div class="ev-top"><span class="date">06 févr.</span><span class="ind">CBNPC de stade III localement avancé non opérable, consolidation après chimioradiothérapie, PD-L1 &ge;1 % (étude PACIFIC) <span class="code"><a href="https://www.has-sante.fr/jcms/c_2908478/fr/imfinzi-durvalumab-cancer-bronchique-non-a-petites-cellules-2eme-ligne" target="_blank" rel="noopener">· CT-17432</a></span></span><div class="badges"><span class="b b-smr">SMR Important</span><span class="b b-a3">ASMR III</span></div></div><div class="ctx">Inscription initiale, première indication remboursée, niveau d'ASMR maximal atteint</div></div>
268
+
269
+ <div class="yr">2021</div>
270
+ <div class="ev"><div class="ev-top"><span class="date">10 mars</span><span class="ind">Cancer bronchique à petites cellules de stade étendu, 1re ligne (association carboplatine/cisplatine + étoposide, étude CASPIAN) <span class="code"><a href="https://www.has-sante.fr/jcms/p_3242177/fr/imfinzi-durvalumab-cancer-bronchique-a-petites-cellules-a-un-stade-etendu-cbpc-se" target="_blank" rel="noopener">· CT-18920</a></span></span><div class="badges"><span class="b b-smr">SMR Important</span><span class="b b-a4">ASMR IV</span></div></div></div>
271
+
272
+ <div class="yr">2023</div>
273
+ <div class="ev"><div class="ev-top"><span class="date">24 mai</span><span class="ind">Carcinome hépatocellulaire avancé ou non résécable, 1re ligne, en association au trémélimumab (étude HIMALAYA) <span class="code"><a href="https://www.has-sante.fr/jcms/p_3448228/fr/imjudo-/-imfinzi-tremelimumab-/-durvalumab-carcinome-hepato-cellulaire-chc" target="_blank" rel="noopener">· CT-20226</a></span></span><div class="badges"><span class="b b-smr">SMR Important</span><span class="b b-a4">ASMR IV</span></div></div></div>
274
+ <div class="ev"><div class="ev-top"><span class="date">21 juin</span><span class="ind">Cancer des voies biliaires non résécable ou métastatique, 1re ligne (association gemcitabine + cisplatine, étude TOPAZ-1) <span class="code"><a href="https://www.has-sante.fr/jcms/p_3451406/fr/imfinzi-durvalumab-cancer-des-voies-biliaires-cvb" target="_blank" rel="noopener">· CT-20175</a></span></span><div class="badges"><span class="b b-smr">SMR Important</span><span class="b b-a4">ASMR IV</span></div></div></div>
275
+ <div class="ev restr"><div class="ev-top"><span class="date">30 août</span><span class="ind">CBNPC métastatique 1re ligne, association durvalumab + trémélimumab + chimiothérapie (étude POSEIDON) <span class="code"><a href="https://www.has-sante.fr/jcms/p_3459834/fr/imfinzi-/-tremelimumab-astrazeneca-durvalumab-/-tremelimumab-cancer-bronchique-non-a-petites-cellules-cbnpc" target="_blank" rel="noopener">· CT-20228</a></span></span><div class="badges"><span class="b b-warn">SMR Modéré</span><span class="b b-a4">ASMR IV</span></div></div><div class="ctx">SMR abaissé sous Important</div></div>
276
+
277
+ <div class="yr">2025</div>
278
+ <div class="ev"><div class="ev-top"><span class="date">15 janv.</span><span class="ind">Cancer de l'endomètre avancé ou récidivant, statut pMMR/MSS, durvalumab + olaparib (étude DUO-E) <span class="code"><a href="https://www.has-sante.fr/jcms/p_3590639/fr/imfinzi-lynparza-durvalumab/olaparib-cancer-de-l-endometre" target="_blank" rel="noopener">· CT-21088</a></span></span><div class="badges"><span class="b b-smr">SMR Important</span><span class="b b-a4">ASMR IV</span></div></div></div>
279
+ <div class="ev"><div class="ev-top"><span class="date">15 janv.</span><span class="ind">Cancer de l'endomètre avancé ou récidivant, statut dMMR/MSI-H, durvalumab (étude DUO-E) <span class="code"><a href="https://www.has-sante.fr/jcms/p_3590636/fr/imfinzi-durvalumab-cancer-de-l-endometre" target="_blank" rel="noopener">· CT-21117</a></span></span><div class="badges"><span class="b b-smr">SMR Important</span><span class="b b-a4">ASMR IV</span></div></div></div>
280
+ <div class="ev refus"><div class="ev-top"><span class="date">22 oct.</span><span class="ind">Cancer du poumon : service médical rendu insuffisant dans l'indication de l'AMM <span class="code"><a href="https://www.has-sante.fr/jcms/p_3745725/fr/imfinzi-durvalumab-cancer-bronchique-non-a-petites-cellules-cbnpc" target="_blank" rel="noopener">· CT-21398</a></span></span><div class="badges"><span class="b b-refus">SMR Insuffisant</span><span class="b b-na">ASMR sans objet</span></div></div><div class="ctx">Refus de prise en charge</div></div>
281
+ <div class="ev"><div class="ev-top"><span class="date">17 déc.</span><span class="ind">Cancer bronchique à petites cellules de stade limité, consolidation après chimioradiothérapie (étude ADRIATIC) <span class="code"><a href="https://www.has-sante.fr/jcms/p_3809520/fr/imfinzi-durvalumab-cancer-bronchique-a-petites-cellules-de-stade-limite-cbpc-sl" target="_blank" rel="noopener">· CT-21376</a></span></span><div class="badges"><span class="b b-smr">SMR Important</span><span class="b b-a4">ASMR IV</span></div></div></div>
282
+
283
+ <div class="yr">2026</div>
284
+ <div class="ev"><div class="ev-top"><span class="date">04 févr.</span><span class="ind">Cancer de la vessie infiltrant le muscle (TVIM) résécable, traitement périopératoire (néoadjuvant puis adjuvant, étude NIAGARA) <span class="code"><a href="https://www.has-sante.fr/jcms/p_3859386/fr/imfinzi-durvalumab-cancer-de-la-vessie-tvim" target="_blank" rel="noopener">· CT-21546</a></span></span><div class="badges"><span class="b b-smr">SMR Important</span><span class="b b-a4">ASMR IV</span></div></div><div class="ctx">Dernière évaluation Transparence enregistrée</div></div>
285
+
286
+ </div>
287
+ </section>
288
+
289
+ <footer>
290
+ <div class="src"><i class="ph-fill ph-database"></i><div><strong>Source :</strong> avis de la HAS (Commission de la Transparence), consolidés et structurés dans <span class="db-tag">OIP Databank<sup>®</sup></span>. Les niveaux de SMR et d'ASMR ainsi que les motifs de refus proviennent de données déjà structurées, garantissant une lecture fidèle des avis officiels. Données arrêtées à juillet 2026.</div></div>
291
+ <div class="src"><i class="ph-fill ph-info"></i><div><strong>Périmètre :</strong> 10 avis de la Commission de la Transparence assortis d'un SMR et, le cas échéant, d'un ASMR, dont plusieurs en association (trémélimumab, olaparib). Les décisions d'accès précoce (11 au catalogue, 3 protocoles d'utilisation thérapeutique) sont présentées dans la section dédiée.</div></div>
292
+ <div class="sig">TEKKARE<br>INSPIRED BY HEALTHCARE</div>
293
+ </footer>
294
+
295
+ </div>
296
+ </body>
297
+ </html>